Neola Medical (Q4 Review): Eyes on upcoming clinical data - Redeye

Redeye provides an update following Neola Medical’s Q4 2025 report. The quarterly figures did not contain any major surprises, and the main focus remains on the upcoming insights from the Swedish clinical study. We make only minor adjustments to our estimates, but we have updated our assumptions regarding capital raising, which results in a revised fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1149522/neola-medical-q4-review-eyes-on-upcoming-clinical-data?utm_source=finwire&utm_medium=RSS